Drug Delivery across the Blood–Brain Barrier
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmaceutical Technology".
Deadline for manuscript submissions: 25 May 2024 | Viewed by 172
Special Issue Editor
Interests: fast-dissolving oral films; three-dimensional printing; fused deposition modelling; inkjet method; nanofibers; liposomes; natural products
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Brain diseases, disorders, and injuries involve damage to the neurons, with devastating outcomes and a considerable societal and economic impact of over USD 1.06tn. Brain diseases include multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, motor neuron disease, ischemic stroke, haemorrhagic stroke, and cancer. Several medicines and interventions have been developed for the treatment of brain diseases, improving the clinical outcomes. However, we are far from the desired therapeutic targets. Brain remyelination and resolving brain inflammation are unmet needs which require researcher’s attention. Although multiple investigations have been conducted in this field, due to complex nature of brain diseases, brain physiology, and anatomy, progress is slow. Therefore, further research on drug delivery to the brain is needed, and drug delivery systems must be optimised on a continuous basis.
This Special Issue will delve into novel drug delivery systems for the treatment of brain diseases, disorders, and injuries, including those that cross the blood–brain barrier and deliver cargo. Novel approaches for the treatment of neuroinflammation and remyelination will also be presented.
The following approaches will also be considered:
- Nose-to-brain drug delivery;
- Pharmaceutical approaches to normalising blood–brain barrier function;
- Use of nanoparticles and ICV injections for drug delivery to the brain;
- Employing magnetically guided nanoparticles as drug carriers;
- The use of biomimetic nanoparticles to target inflammation in the brain;
- The use of peptide-based self-assembled nanoparticles;
- Employing solid lipid nanoparticles for the delivery of siRNA to brain neurons;
- Nanoparticles to promote remyelination in the brain;
- Nanoparticles for the treatment of traumatic brain injury.
Dr. Touraj Ehtezazi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- blood–brain barrier
- drug delivery
- brain diseases
- neuroinflammation
- remyelination
